Basic Hematology Overview
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Large Pink Inclusions in Multiple Myeloma Cells
Journal of Blood Disorders, Symptoms & Treatments Case Report Large Pink Inclusions in Multiple Myeloma Cells This article was published in the following Scient Open Access Journal: Journal of Blood Disorders, Symptoms & Treatments Received July 28, 2017; Accepted August 05, 2017; Published August 11, 2017 Juan Zhang1, Mingyong Li1*, Xianyong Jiang2 and Yuan He1 Abstract 1Clinical Laboratory of Sichuan Academy of Medical Objective: Several intracytoplasmic morphological changes in the plasma cells of Science & Sichuan Provincial People’s Hospital, multiple myeloma have been described previously, especially the Auer rod-like inclusions, Chengdu, Sichuan, China but large pink inclusions have not been reported yet. In this paper, we intend to report a rare 2 Haematology Bone Marrow Inspection laboratory case of inclusions in multiple myeloma. of Peking Union Medical College Hospital, Beijing, China Methods: Bone marrow aspiration from the right superior iliac spine was examined twice. Cells were stained with “Wright-Giemsa” method and also analyzed by flow cytometry, immunohistochemical staining and fluorescence in situ hybridization (FISH). Bone scan demonstrated bilateral ribs, thoracic vertebrae, with multiple low density shadows, which was confirmed subsequently as a lytic lesion on CT scanning. Complete blood count, serum chemistry and coagulation tests were also examined. Results: Bone marrow aspirate from the right superior iliac spine at the time of myeloma diagnosis showed about 58.5% of all nucleated cells being plasma cells, of which many had large pink intracytoplasmic inclusions. Repeat bone marrow biopsy later showed persistence of these morphological findings. All of Flow cytometry, immunohistochemistry and FISH examination support the diagnosis of multiple myeloma. Conclusion: This is the first time to report a multiple myeloma case with such giant pink inclusions. -
Blood, Lymph, and Immunity Joann Colville
Blood, Lymph, and Immunity Joann Colville CHAPTER OUTLINE .»: BLOOD Function Introduction Lymphatic Structures Plasma THE IMMUNE SYSTEM Cellular Components of Blood Function Red Blood Cells Immune Reactions Platelets Immunization: Protection Against Disease White Blood Cells THE LYMPHATICSYSTEM Lymph Formation Characteristics LEARNING OBJECTIVES • List and describe the functions of blood • List the functions of the lymphatic system • Describe the composition of blood plasma • Describe the structure and functions of the lymph nodes, • Describe the characteristics of mature erythrocytes spleen, thymus, tonsils, and GALT Describe the structure of the hemoglobin molecule and • List the functions of the immune system explain the fate of hemoglobin following intravascular and • Differentiate between specific and nonspecific immune extravascular hemolysis reactions • Give the origin of thrombocytes and describe their • Differentiate between cell-mediated and humoral immunity characteristics and functions • List the components involved in cell-mediated immunity • Listthe types of leukocytes and describe the functions of each and explain the role of each • Describe the formation of lymph fluid and its circulation List and describe the classes of immunoglobulins through the lymphatic system • Differentiate between active and passive immunity BLOOD vessels of the cardiovascular system. It has three main func- tions: transportation, regulation, and defense. INTRODUCTION Blood. Say the word, and some people cringe, others faint, Function and if you believe authors Bram Stoker, Stephen King, and 1. Blood is a transport system. Christopher Moore (all authors of vampire books), others • It carries oxygen, nutrients, and other essential com- drool. But no matter what you think about blood, animals pounds to every living cell in the body. -
The Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Role of Flow Cytometry
THE DIAGNOSIS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: ROLE OF FLOW CYTOMETRY Alberto Orfao Department of Medicine, Cancer Research Centre (IBMCC-CSIC/USAL), University of Salamanca, Salamanca, Spain Paroxysmal nocturnal hemoglobinuria (PNH) on one or multiple populations of peripheral blood is an acquired clonal disorder typically affecting red cells and/or leucocytes of PNH patients, this young adults, which involves the phosphatidylino- translating into a new diagnostic test. Because sitol glycan anchor biosynthesis class A gene of this flow cytometry became an essential tool (PIGA) coded in chromosome X, in virtually every in the diagnosis of PNH. In turn, it could be also case. The altered gene encodes for a defective pro- demonstrated that investigation of the presence of tein product, the pig-a enzyme which is involved GPI-deficient cells among circulating mature neu- in the early steps of the synthesis of glycosylphos- trophils and monocytes, increases the sensitivity phatidylinositol (GPI). This later molecule (GPI) of red blood cell screening because of the shorter acts as an anchor of a wide range of proteins to lifetime of both populations of leucocytes. Despite the cell surface. At present a large number of GPI- all the above, routine assessment of CD55 and anchor associated proteins have been described CD59 is also associated with several limitations which are expressed by one or multiple distinct due to distinct patterns of expression among dif- compartments of hematopoietic cells. The altered ferent cell populations, dim and heterogeneous PIGA gene leads to an altered GPI anchor which expression among normal individuals and the lack leads to defective expression of GPI-AP on the of experience in many labs as regards the normal cytoplasmic membrane, on the cell surface. -
PATHOLOGY RESIDENT HEMATOLOGY ROTATION (North Florida/South Georgia Veterans Health Care System): Rotation Director: William L
PATHOLOGY RESIDENT HEMATOLOGY ROTATION (North Florida/South Georgia Veterans Health Care System): Rotation Director: William L. Clapp, M.D., Chief, Hematology Section, Gainesville VAMC; Consultants: Neil S. Harris, M.D., Director, Laboratory Hematology/Coagulation, University of Florida and Shands Hospital and Raul C. Braylan, M.D., Director, Hematopathology, University of Florida and Shands Hospital 1. Description of the Rotation: In this rotation, the resident will gain experience in laboratory hematology, which will include (1) peripheral blood studies to evaluate a variety of hematologic disorders, including anemias, lymphoproliferative and myeloproliferative disorders and leukemias. The emphasis on a multidisciplinary approach to diagnose hematologic disorders (including correlation of the peripheral blood studies with bone marrow and lymph node studies) provides an opportunity for the resident to also gain additional experience in (2) traditional histopathology, (3) immunohistochemistry, (4) electron microscopy, (5) protein electrophoresis, (6) flow cytometry, (7) cytogenetics and (8) molecular genetics which may be performed on the peripheral blood, bone marrow or lymph nodes of patients. The residents will acquire valuable experience by independently performing some bone marrow procedures. In addition, the resident will gain experience in coagulation testing. The residents will become familiar with the instrumentation in the hematology laboratory, including the operating principles and trouble-shooting (medical knowledge). The availability of assembled case study sets and reading materials (medical knowledge) will enhance the resident’s experience. Participation in CAP surveys, continuing education and hematology conferences is a component of the rotation (practice-based learning). Management issues and computer applications will be discussed (practice-based learning). As appropriate to the individual case or consultation under review, the ethical, socioeconomic, medicolegal and cost-containment issues will be reviewed and discussed. -
Section 8: Hematology CHAPTER 47: ANEMIA
Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited. -
Coagulation Testing: High Hematocrit-Anticoagulant Adjustment
PREANALYTIC PULSE Coagulation Testing: High Hematocrit-Anticoagulant Adjustment In 1980, CLSI released H21-A4 guidelines for coagulation testing, which included the recommendation to adjust/correct the amount of citrate in blue-top evacuated blood collection tubes for patients presenting hematocrits greater than 55%. In addition to the CLSI guidelines, the CAP hematology checklist HEM.22830 includes the question, “Are there documented guidelines for the detection and special handling of specimens with elevated hematocrits?” Principle The adjustment is to assure the plasma:anticoagulant ratio (not the blood:anticoagulant ratio) stays consistent. A patient with high hematocrit, greater than 55%, will result in less plasma after centrifugation. The plasma fraction will contain an increased concentration of sodium citrate anticoagulant. The increased concentration may result in falsely prolonged test results for Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT). Formula 1. To calculate the corrected 3.2% sodium citrated whole blood for hematocrit > 55%, adjust the citrate to the proper volume with the following formula: -3 C = (1.85 x 10 )(100-HCT)(Vblood) Where: C = volume of sodium citrate required for that volume of blood HCT = patient’s hematocrit V = volume of blood required in the blood collection tube (example if a 3mL tube is used the blood draw volume is 2.7mL) 1.85 x 10-3 is a constant (considering the citrate volume, blood volume, and citrate concentration). 2. Example: Patient has a Hct of 60% and the patient’s blood will be drawn into a 3mL VACUETTE® sodium citrate (blue-top) blood collection tube. Adjustment of the sodium citrate volume is calculated as: C = (1.85 x 10-3)(100-60)(2.7mL) C = 0.20mL (rounded up from 01.998mL) Remove: 0.30 - 0.20 = 0.10mL of sodium citrate to be removed (0.30 is the difference between the total tube volume of 3.0mL and the blood drawn into the tube of 2.7mL) Method The instructions to prepare an adjusted sodium citrate tube are to be documented in the Laboratory Standard Operating Procedures. -
Acquired Hemophilia A: Pathogenesis and Treatment
Bleeding disorders Acquired hemophilia A: pathogenesis and treatment P.W. Collins ABSTRACT Arthur Bloom Haemophilia Centre, Acquired hemophilia A is an autoimmune disease caused by an inhibitory antibody to factor VIII. The School of Medicine, severity of bleeding varies but patients remain at risk of life-threatening bleeding until the inhibitor Cardiff University, Heath Park, has been eradicated. The cornerstones of management are rapid and accurate diagnosis, control of Cardiff, UK bleeding, investigation for an underlying cause, and eradication of the inhibitor by immunosuppres - sion. Patients should be managed jointly with a specialist center even if they present without signifi - cant bleeding. Despite an extensive literature, few controlled data are available and management Hematology Education: guidelines are based on expert opinion. Recombinant factor VIIa and activated prothrombin complex the education program for the concentrate are equally efficacious for treating bleeds and both are superior to factor VIII or desmo - annual congress of the European pressin. Immunosuppression should be started as soon as the diagnosis is made. Commonly used reg - Hematology Association imens are steroids alone or combined with cytotoxic agents. Rituximab is being used more commonly but current evidence does not suggest that it improves outcomes or reduces side effects. 2012;6:65-72 Introduction Pathogenesis Acquired hemophilia A (AHA) is a bleed - AHA is associated with autoimmune dis - ing disorder caused by polyclonal IgG1 and eases, such as rheumatoid arthritis, polymyal - IgG4 autoantibodies to the factor VIII ( FVIII ) gia rheumatic, and systemic lupus erythe - A2 and C2 domain. Morbidity and mortality matosis; malignancy; pregnancy and dermato - are high secondary to age, underlying dis - logical disorders, such as pemphigoid. -
Chapter 06 Lecture Outline
Chapter 06 Lecture Outline See separate PowerPoint slides for all figures and tables pre- inserted into PowerPoint without notes. Copyright © 2016 McGraw-Hill Education. Permission required for reproduction or display. 1 Cardiovascular System: Blood © SPL/Science Source, (inset) © Andrew Syred/Science Source 2 Points to ponder • What type of tissue is blood and what are its components? • What is found in plasma? • Name the three formed elements in blood and their functions. • How does the structure of red blood cells relate to their function? • Describe the structure and function of each white blood cell. • What are disorders of red blood cells, white blood cells, and platelets? • What do you need to know before donating blood? • What are antigens and antibodies? • How are ABO blood types determined? • What blood types are compatible for blood transfusions? • What is the Rh factor and how is this important to pregnancy? • How does the cardiovascular system interact with other systems to maintain homeostasis? 3 6.1 Blood: An Overview What are the functions of blood? • Transportation: oxygen, nutrients, wastes, carbon dioxide, and hormones • Defense: against invasion by pathogens • Regulatory functions: body temperature, water- salt balance, and body pH 4 6.1 Blood: An Overview What is the composition of blood? • Remember: blood is a fluid connective tissue. • Formed elements are produced in red bone marrow. – Red blood cells/erythrocytes (RBCs) – White blood cells/leukocytes (WBCs) – Platelets/thrombocytes 5 6.1 Blood: An Overview What is the composition of blood? • Plasma – It consists of 91% water and 9% salts (ions) and organic molecules. – Plasma proteins are the most abundant organic molecules. -
Research Article
z Available online at http://www.journalcra.com INTERNATIONAL JOURNAL OF CURRENT RESEARCH International Journal of Current Research Vol. 8, Issue, 12, pp.42994-42999, December, 2016 ISSN: 0975-833X RESEARCH ARTICLE PLASMA CELLS IN HEALTH AND DISEASE *Karuna Kumari, Shwetha Nambiar, K., Vanishree C Haragannavar, Dominic Augustine, Sowmya, S. V. and Roopa S Rao Faculty of Dental Sciences, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka ARTICLE INFO ABSTRACT Article History: Plasma cells are the only cells that sustain antibody production and hence are an essential part of immune system. In the bone marrow plasma cells produce immunoglobulins which assure long-term Received 03rd September, 2016 Received in revised form humoral immune protection and in the mucosa-associated lymphoid tissues (MALT) plasma cells 16th October, 2016 secrete IgA which protect the individual from pathogens invasion. This review illustrates plasma cell Accepted 25th November, 2016 development and their role in both health and disease. Published online 30th December, 2016 Key words: Plasma cell, Immunoglobulin, B cells. Copyright©2016, Karuna Kumari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Citation: Karuna Kumari, Shwetha Nambiar, K., Vanishree C Haragannavar, Dominic Augustine, Sowmya, S. V. and Roopa S Rao, 2016. “Plasma cells in health and disease”, International Journal of Current Research, 8, (12), 42994-42999. INTRODUCTION cytoplasm of the PCs contains large amount of rough endoplasmic reticulum (rER) and Golgi apparatus. The Plasma Cells (PCs) are non-dividing, effectors cells that cytoplasm of PC displays strong basophilia due to presence of represent the final stage of B cell differentiation. -
Clinical Usefulness of Serum Procalcitonin Level in Distinguishing Between Kawasaki Disease and Other Infections in Febrile Children
Original article LeeKorean NY, Jet Pediatr al. • Serum 2017;60(4):112-117 procalcitonin level between Kawasaki disease and other infections https://doi.org/10.3345/kjp.2017.60.4.112 pISSN 1738-1061•eISSN 2092-7258 Korean J Pediatr Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children Na Hyun Lee, MD1, Hee Joung Choi, MD1, Yeo Hyang Kim, MD2 1Department of Pediatrics, Keimyung University School of Medicine, Daegu, 2Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea Purpose: The aims of this study were to compare serum procalcitonin (PCT) levels between febrile Corresponding author: Yeo Hyang Kim, MD, PhD children with Kawasaki disease (KD) and those with bacterial or viral infections, and assess the clinical Department of Pediatrics, Kyungpook National Uni- versity School of Medicine, 680 Gukchaebosang-ro, usefulness of PCT level in predicting KD. Jung-gu, Daegu 41944, Korea Methods: Serum PCT levels were examined in febrile pediatric patients admitted between August 2013 Tel: +82-53-200-5720, and August 2014. The patients were divided into 3 groups as follows: 49 with KD, 111 with viral infec- Fax: +82-53-425-6683, tions, and 24 with bacterial infections. E-mail: [email protected] Results: The mean PCT level in the KD group was significantly lower than that in the bacterial infection Received: 26 August, 2016 group (0.82±1.73 ng/mL vs. 3.11±6.10 ng/mL, P=0.002) and insignificantly different from that in Revised: 27 October, 2016 the viral infection group (0.23±0.34 ng/mL,P=0.457). -
Hereditary Spherocytosis: Clinical Features
Title Overview: Hereditary Hematological Disorders of red cell shape. Disorders Red cell Enzyme disorders Disorders of Hemoglobin Inherited bleeding disorders- platelet disorders, coagulation factor Anthea Greenway MBBS FRACP FRCPA Visiting Associate deficiencies Division of Pediatric Hematology-Oncology Duke University Health Service Inherited Thrombophilia Hereditary Disorders of red cell Disorders of red cell shape (cytoskeleton): cytoskeleton: • Mutations of 5 proteins connect cytoskeleton of red cell to red cell membrane • Hereditary Spherocytosis- sphere – Spectrin (composed of alpha, beta heterodimers) –Ankyrin • Hereditary Elliptocytosis-ellipse, elongated forms – Pallidin (band 4.2) – Band 4.1 (protein 4.1) • Hereditary Pyropoikilocytosis-bizarre red cell forms – Band 3 protein (the anion exchanger, AE1) – RhAG (the Rh-associated glycoprotein) Normal red blood cell- discoid, with membrane flexibility Hereditary Spherocytosis: Clinical features: • Most common hereditary hemolytic disorder (red cell • Neonatal jaundice- severe (phototherapy), +/- anaemia membrane) • Hemolytic anemia- moderate in 60-75% cases • Mutations of one of 5 genes (chromosome 8) for • Severe hemolytic anaemia in 5% (AR, parents ASx) cytoskeletal proteins, overall effect is spectrin • fatigue, jaundice, dark urine deficiency, severity dependant on spectrin deficiency • SplenomegalSplenomegaly • 200-300:million births, most common in Northern • Chronic complications- growth impairment, gallstones European countries • Often follows clinical course of affected -
Haemophilia a Is the Most Common Form – Affecting
Haemophilia is an inherited, serious It can dramatically reduce bleeding disorder where a person’s the quality of life of people blood does not clot properly, leading affected, as well as their family, to uncontrolled bleeding which can friends and caregivers1. occur spontaneously or after minor trauma. Haemophilia A is the most common form – affecting 50-60% of whom have severe haemophilia4. blood of a person In a healthy person, proteins called clotting factors work together to form a blood clot and help stop bleeding. People with haemophilia A either lack or do not have enough of a clotting factor called which leads to their blood not being able to clot properly. Bruising Repeated bleeding into muscles and joints, which can lead to long term disability or joint disease5 Spontaneous bleeding, which can be life threatening if it occurs in vital organs, such as the brain Prolonged and uncontrolled bleeding following injury or surgery6,7 Life for people with haemophilia and their caregivers is often centred on treatment infusions, taking up a large amount of time and having a significant impact on their lives8. People with haemophilia A report difficulty balancing treatment with daily life, so compliance can be a challenge9,10 leaving them vulnerable to potentially dangerous bleeds. The mainstay of current treatment for haemophilia A is factor VIII replacement therapy, which is taken on-demand (as needed to treat bleeds), or on an ongoing basis (to prevent bleeds). It is short-acting and so needs to be administered frequently (at least twice a week)2 by the patient or a caregiver and for some, especially children, finding a vein for medicine infusion can be difficult11.